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Complement is part of the innate immune system
and plays a fundamental role in the clearance of im-
mune complexes and cell debris. The main effector
mechanisms of complement activation are induction
of inﬂammatory response and phagocytosis and cell
lysis. However, complement activation is a double-
edged sword and has the potential to damage self-
tissues. In order to avoid self-damage, there is an
absolute need for strict control by ﬂuid-phase and
membrane-bound regulatory proteins. Thus, an
underperforming regulatory system (due to either
genetic or acquired abnormalities) can shift the bal-
ance between regulation and activation toward the
latter and lead to tissue injury in response to otherwise
innocuous stimuli. Deposition of both actived com-
plement fragments from plasma in glomeruli and
complement locally produced and activated in the
kidney may contribute to many kidney disorders,
including lupus nephritis, postinfectious glomerulo-
nephritis, membranous nephropathy, antineutrophil
cytoplasmic antibody vasculitis, and anti–glomerular
basement membrane (anti-GBM) glomerulonephritis.
Interest in the complement system has been boosted
in the past 15 years by the discovery that rare devas-
tating kidney diseases, including atypical hemolytic
uremic syndrome (aHUS) and membranoproliferative
glomerulonephritis (MPGN), are disorders of com-
plement regulation.
Additional Readings
» Nangaku M. Complement regulatory proteins in glomerular
diseases. Kidney Int. 1998;54(5):1419-1428.
» Ricklin D, Hajishengallis G, Yang K, et al. Complement: a
key system for immune surveillance and homeostasis. Nat
Immunol. 2010;11(9):785-797.
» Thurman JM. Complement in kidney disease: core curricu-
lum 2015. Am J Kidney Dis. 2015;65(1):156-168.
» Vieyra MB, Heeger PS. Novel aspects of complement in
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The complement system is organized in 3 activa-
tion pathways (the alternative, classical, and lectin
pathways) and a common terminal pathway (Fig 1).
Activation of the 3 pathways leads to the formation ofy Dis. 2015;66(2):359-375protease complexes (C3 convertases) that cleave C3
into C3a and C3b.
The classical and lectin pathways are triggered
by recognition of pathogens or damaged cell surfaces
by antibodies and recognition molecules (Fig 1).
The alternative pathway undergoes constant low-
grade activation in the ﬂuid phase by spontaneous
hydrolysis of C3 that, through the formation of the
alternative pathway initiation C3 convertase (C3[H2O]
Bb), is responsible for deposition of a low amount of
C3b onto cell surfaces (Fig 1). C3b deposited on
bacterial cells binds receptors on leukocytes and
initiates phagocytosis. In addition, C3b binds factor
B (CFB) and forms the surface-localized C3 con-
vertase C3bBb, which cleaves additional C3 mole-
cules into C3b and C3a, resulting in a positive-
feedback loop. The binding of additional C3b to
C3 convertases forms C5 convertases, which cleave
C5, producing C5a and C5b. C5a and C3a are potent
chemoattractants for phagocytes and induce endo-
thelial activation. C5b together with C6, C7, C8, and
C9 form the terminal pathway complex (C5b-9),
which leads to cell lysis (Fig 1).
Self-surfaces are protected from complement
damage by a set of regulators (Fig 1) that are either
membrane anchored or in the ﬂuid phase. Regulatory
proteins prevent formation of the C3 convertases,
foster inactivation of C3b (iC3b) by factor I (CFI;
cofactor activity), dissociate C3 convertase and C5
convertase (decay acceleration activity), or prevent
C5b-9 complex assembly (Figs 1 and 2). Perturbation359
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Figure 1. The 3 complement activation pathways. Bold text denotes complement-regulatory molecules; red text, proteins with ge-
netic defects that have been associated with atypical hemolytic uremic syndrome (aHUS) and/or membranoproliferative glomerulop-
athy (MPGN)/C3 glomerulopathy (C3G). Abbreviations and definitions: C3(H2O)Bb, alternative pathway initiation convertase; C1inh,
C1 inhibitor (inactivates C1r and C1s, MASP-1, and MASP-2); FB, complement factor B; FD, complement factor D; FH, complement
factor H (binds C3b, exerts cofactor activity for FI-mediated C3b cleavage, prevents the formation of the alternative pathway C3 con-
vertase, and destabilizes (decay accelerating activity) the alternative pathway C3 and C5 convertases); C4BP, C4b-binding protein
(binds to C4b and has decay accelerating activity for the classical pathway C3 convertase and cofactor activity for FI-mediated
C4b cleavage); CD59, protectin (with vitronectin and clusterin, prevents C5b-9 formation); CR1, complement receptor 1 (has decay
accelerating activity as well as cofactor activity for FI-mediated C3b and C4b cleavage); DAF, decay accelerating factor (has decay
accelerating activity on C3/C5 convertases of the classical and alternative pathways); FI, complement factor I (degrades C3b and
C4b, aided by cofactors); Ig, immunoglobulin; MASP, MBL-associated serine proteases; MBL, mannose binding lectin; MCP, mem-
brane cofactor protein (exerts cofactor activity for FI-mediated C3b cleavage); P, properdin.
Noris and Remuzziof the balance between complement activators and
regulators provides the molecular basis of aHUS
and MPGN/C3 glomerulopathy (C3G).
Additional Readings
» Noris M, Remuzzi G. Overview of complement activation
and regulation. Semin Nephrol. 2013;33(6):479-492.
» Pickering MC, Cook HT. Translational mini-review series on
complement factor H: renal diseases associated with com-
plement factor H: novel insights from humans and animals.
Clin Exp Immunol. 2008;151(2):210-230.
» Thurman JM. Complement in kidney disease: core curricu-
lum 2015. Am J Kidney Dis. 2015;65(1):156-168.
» Walport MJ. Complement. First of two parts. N Engl J Med.
2001;344(14):1058-1066.
» Zipfel PF, Skerka C. Complement regulators and inhibitory
proteins. Nat Rev Immunol. 2009;9(10):729-740.360ATYPICAL HEMOLYTIC UREMIC SYNDROME
Hemolytic uremic syndrome (HUS) is a rare disease
deﬁned by the triad of nonimmune (Coombs negative)
microangiopathic hemolytic anemia, thrombocytopenia,
and acute kidney injury. In children, the disease is most
commonly associated with infection by Escherichia
coli strains that produce Shiga toxins (STEC-HUS;
Table 1). Approximately 5% of HUS cases in children
result from infection by neuroaminidase-producing
Streptococcus pneumoniae (pneumococcal-HUS or
neuraminidase-associated HUS, usually Coombs pos-
itive; Table 1).
aHUS has been used to describe those rare cases
(,10%) in which infections by Shiga toxin–producing
bacteria or S pneumoniae or other secondary causesAm J Kidney Dis. 2015;66(2):359-375
Figure 2. Model for the mechanisms leading from impaired regulation of the alternative pathway to hemolytic uremic syndrome
(HUS). (A) Pathway in unaffected individuals. Factor H (FH) binds to the glycosaminoglycans and to C3b on endothelial surface
and prevents the interaction of C3b with factor B (FB) to form the alternative pathway C3 convertase. In addition, together with mem-
brane cofactor protein (MCP), FH acts as cofactor for factor I (FI)-mediated cleavage of C3b. FH also dissociates the C3 convertase of
the alternative pathway (not shown). Thrombomodulin (THBD) enhances FI-mediated inactivation of C3b in the presence of FH. (B)
Pathway in patients with mutations in complement regulatory genes for FH, MCP, FI, and THBD (loss-of-function mutants are indicated
with dashed lines). C3b is not degraded efficiently and forms the C3 and C5 convertases of the alternative pathway. C5b initiates as-
sembly of the terminal complement complex (C5b-9), leading (together with C5a) to cell injury and activation, with exocytosis of adhe-
sion molecules (P-selectin) and von Willebrand factor (VWF), which favor platelet adhesion and aggregation, and expression of tissue
factor, which activates coagulation. Subsequent cell detachment exposes the subendothelial matrix, followed by VWF binding to
collagen, which amplifies the prothrombotic state. Aggregated platelets release procoagulant microvesicles (PMV) containing tissue
factor, which facilitate assembly of clotting enzymes. A similar picture applies to patients with gain-of-function mutations in FB and
C3 (indicated with thick lines). Mutant C3b does not bind FH and MCP and is resistant to degradation by FI. Both mutant C3 and mutant
FB form a superconvertase that is resistant to dissociation by surface complement regulators. Abbreviations: aHUS, atypical HUS;
GAG, glycosaminoglycans.
Complement-Dependent Glomerular Disease(Table 1) can be excluded. aHUS is an extremely
rare disease. The annual incidence is about 0.5 to 2
per million adults and 3.3 per million children or
adolescents.Am J Kidney Dis. 2015;66(2):359-375A differential diagnosis among the different forms
of HUS is often not feasible based only on age of
onset or clinical symptoms. In infants younger than
6 months, complement-mediated aHUS is most361
Table 1. Classification of HUS
Name Causes
STEC-HUS Infection with Shiga toxin–secreting
strains of Escherichia coli or
Shigella dysenteriae
Pneumococcal-HUS Infection with neuroaminidase-
producing Streptococcus
pneumoniae
Atypical HUS
Complement-mediated Mutations (mostly heterozygous)
in CFH, CFI, MCP, C3, CFB,
and THBD genes; genomic
rearrangements of CFH/CFHR
loci; anti-CFH autoantibodies
DGKE-deficiency
associated
Homozygous and compound
heterozygous mutations in the
DGKE gene
Cobalamin deficiency–
associated HUS
Homozygous mutations in the
MMACHC gene
Secondary HUS Drugs (quinine, VEGF inhibition,
antiviral, cancer chemotherapy),
autoimmune diseases (SLE,
scleroderma, antiphospholipid
syndrome), malignancy, bone
marrow transplantation
Abbreviations: CFB, complement factor B; CFH, complement
factor H; CFHR, complement factor H–related; CFI, complement
factor I; DGKE, diacylglycerol kinase ε; HUS, hemolytic uremic
syndrome; MCP, membrane cofactor protein; MMACHC, methyl-
malonic aciduria and homocystinuria type C; STEC-HUS, Shiga-
like toxin–producing Escherichia coli HUS; SLE, systemic lupus
erythematosus; THBD, thrombomodulin; VEGF, vascular endo-
thelial growth factor.
Noris and Remuzzicommon, but pneumococcal-HUS may also occur.
STEC-HUS largely predominates in infants and chil-
dren from 6 months to 5 years, but may occur at any
age. The presence of diarrhea, a characteristic symptom
of STEC-HUS, cannot be used to differentiate between
STEC-HUS and aHUS becausew30%of patients with
aHUS experience diarrhea, often bloody. However,
microbiological, biochemical, and genetic studies may
be of help for differential diagnosis (Fig 3).
In contrast to STEC-HUS, which is characterized by
full recovery in .80% of patients, aHUS presages a
poorer prognosis. Themajority of patients need dialysis
at admission, and until very recently (following the
introduction of the anti-C5 monoclonal antibody ecu-
lizumab), w50% of patients never recovered kidney
function. Mortality after the ﬁrst episode has been re-
ported to be higher in children than in adults, but pro-
gression to end-stage renal disease is more frequent in
adults. At 5 years after onset, 48% of children and 67%
of adults have died or reached end-stage renal disease.
Additional Readings
» Campistol JM, Arias M, Ariceta G, et al. An update for
atypical haemolytic uraemic syndrome: diagnosis and treat-
ment. A consensus document. Nefrologia. 2013;33(1):24-45.362» George JN, Nester CM. Syndromes of thrombotic micro-
angiopathy. N Engl J Med. 2014;371(7):654-666.
» Kavanagh D, Goodship TH, Richards A. Atypical hemolytic
uremic syndrome. Semin Nephrol. 2013;33(6):508-530.
» Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic
syndrome. Orphanet J Rare Dis. 2011;6:60.
» Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome.
N Engl J Med. 2009;361(17):1676-1687.
Histologic Features in aHUS
Broadly, 3 types of lesions are seen in patients with
aHUS. These lesions are not mutually exclusive and
all involve glomerular injury. In the most common
type, glomerular thrombotic microangiopathy (TMA),
glomerular capillary walls are thickened with widen-
ing of the subendothelial space. Endothelial cells may
appear swollen, obstructing the capillary, or detached
from the basement membrane. These lesions are
mainly observed in glomerular capillaries and pre-
glomerular arterioles, whereas larger arteries are only
rarely involved. Glomeruli may be enlarged, with
capillaries distended by red blood cells and platelet-
ﬁbrin thrombi that may also be observed in the aff-
erent arterioles (Fig 4A).
The second type, arterial TMA, also involves ar-
terioles and interlobular arteries. Intimal edema and
proliferation, necrosis of the arterial wall, luminal
narrowing, and thrombosis are observed (Fig 4B).
Glomeruli appear ischemic and shrunken, with wrin-
kling of the basement membranes of the collapsed
capillaries. Arterial TMA is seen more often in re-
lapsing forms with severe hypertension and is asso-
ciated with a poor prognosis.
The third lesion type, cortical necrosis, is patchy or
rarely diffuse to the whole superﬁcial cortex and is
due to the acute cortical ischemia after obstruction of
the local microcirculation. This lesion is more com-
mon in severe cases of STEC-HUS, but is also
observed in aHUS and correlates with chronic kidney
disease.
Glomerular deposits of ﬁbrin or ﬁbrinogen are seen
by immunoﬂuorescence microscopy. Deposits of
complement activation products have also been found
along glomerular capillaries and on the endothelium
of arterioles and small arteries.
Although in aHUS, by deﬁnition, the TMA pre-
dominantly affects kidney vessels, the lesion can
involve the microvasculature of other organs (heart,
intestine, pancreas, lungs, and especially the brain) in
w20% of patients.
Additional Readings
» Habib R. Pathology of the hemolytic uremic syndrome. In:
Kaplan B, Moake J, eds. Hemolytic Uremic Syndrome and
Thrombotic Thrombocytopenic Purpura. New York, NY:
Marcel Dekker; 1992:315-353.
» Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome.
Semin Immunopathol. 2014;36(4):399-420.Am J Kidney Dis. 2015;66(2):359-375
Diagnosis of thrombotic microangiopathy:
- Low platelet count
- Increased serum LDH
- Fragmented erythrocytes in the peripheral smear
<10% ADAMTS-13 
activity
TTP
Infection by
Shiga toxin–producing bacteria
STEC-HUS
aHUS
Autoimmune diseases,
drugs, malignancies…
Secondary HUS
- - -
Screen for CFH, MCP, CFI, C3, CFB, THBD mutations, 
CFH/CFHR rearrangements, and anti-CFH antibodies
Figure 3. Diagnostic algorithm for screening and diagnosis of the different forms of thrombotic microangiopathy. In patients pre-
senting with low platelet count, increased lactate dehydrogenase (LDH), and hemolytic anemia, plasma ADAMTS-13 activity should
be measured: if ,10%, this leads to diagnosis of thrombotic thrombocytopenic purpura (TTP). Positive tests for Shiga-toxin–producing
bacteria in stools are consistent with a diagnosis of Shiga-like toxin–producing Escherichia coli hemolytic uremic syndrome (STEC-
HUS). Diagnosis of atypical HUS (aHUS) is done by exclusion in patients in whom these tests are negative and with no evidence
of secondary conditions. When aHUS is suspected, full screening for complement disease–associated abnormalities (complement fac-
tor H [CFH], membrane cofactor protein [MCP], complement factor I [CFI], C3, complement factor B [CFB], and thrombomodulin
[THBD] mutations; CFH/CFHR rearrangements; and anti-CFH autoantibodies) should be performed. Genetic screening is being per-
formed at the diagnostic level in several centers in Europe (http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search_Simple.php?
lng5EN) and the United States, while detection of genomic rearrangements and anti-CFH antibodies is done only in few specialized
centers for research purposes.
Complement-Dependent Glomerular DiseasePathogenesis
Genetic or acquired abnormalities in the comple-
ment system have been documented in w60% of
patients with aHUS (Table 2).
CFH Mutations, CFH-CFHR Hybrid Genes, and Anti-CFH
Autoantibodies
Complement factor H (CFH) is the most impor-
tant plasma regulator of the alternative pathway. ItA B
Figure 4. (A) Glomerulus from a patient with a glomerular form of
tery in a case of aHUS with severe vascular involvement. The vasc
proliferation. Thrombotic material and erythrocytes can be seen in th
Am J Kidney Dis. 2015;66(2):359-375is composed of 20 domains called short consensus
repeats (SCRs) encoded by 23 exons. The 4 amino-
terminal SCRs mediate the complement-regulatory
functions of the protein (cofactor activity and decay
accelerating activity). Besides regulating complement
in the ﬂuid phase, CFH protects host cells by binding
through its carboxy-terminal SCRs to polyanions
and C3 activation compounds on the cell surface
(Fig 2A).atypical hemolytic uremic syndrome (aHUS). (B) Interlobular ar-
ular lumen is nearly fully occluded. Changes include myointimal
e lumen and within the vascular wall.
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Table 2. Genetic Abnormalities Associated With aHUS
Gene Abnormality Main Effect
Frequency
in aHUS
CFH Heterozygous and (rarely) homozygous
mutations mainly in the last 2 exons
Impaired cell-surface complement regulation 25%-30%
CFH/CFHRs Nonallelic homologous recombinations Impaired cell-surface complement regulation 3%-5%
CFHR1 Deletion and formation of anti-CFH
antibodies
Impaired cell-surface complement regulation 5%-10%
CD46a Heterozygous and (rarely) homozygous
mutations
Reduced surface expression 8%-10%
CFI Heterozygous mutations Low cofactor activity 4%-8%
C3 Heterozygous mutations Resistance to C3b inactivation, C3 convertase
stabilization
4%-8%
CFB Heterozygous mutations C3 convertase stabilization 1%-4%
THBD Heterozygous mutations Reduced TAFI activation, reduced C3b inactivation 3%-4%
DGKE Homozygous or compound
heterozygous mutations
Protein truncation, proinflammatory and
prothrombotic endothelial phenotype, increased
endothelial apoptosis
2%-27% of
infantile
casesb
Abbreviations: aHUS, atypical hemolytic uremic syndrome; CFB, complement factor B; CFH, complement factor H; CFHR, com-
plement factor H–related; CFI, complement factor I; DGKE, diacylglycerol kinase ε; MCP, membrane cofactor protein; TAFI, thrombin-
activatable fibrinolysis inhibitor; THBD, thrombomodulin.
aCD46 encodes MCP.
bOnset of the disease before 1 to 2 years of age.
Noris and RemuzziIn 1998, Warwicker and colleagues described for
the ﬁrst time mutations in the CFH gene in aHUS.
CFH mutations are the most common genetic ab-
normalities in aHUS, with a prevalence of 20% to
30% (http://www.FH-HUS.org; Table 2). The mu-
tations are of all types: nonsense, missense, and
small indels (insertions or deletions). Some patients
have homozygous mutations but most are heterozy-
gous. More than 50% of mutations cluster in
SCR19-20. Some mutations are associated with a
quantitative deﬁcit of CFH, while the majority are
associated with normal CFH levels and result in a
mutant protein that is unable to bind to and regulate
complement at the cell surface (Fig 2B). These mu-
tants have also been shown to have impaired binding to
platelets, resulting in increased complement-mediated
platelet activation and release of tissue factor–
expressing microvesicles. Plasma C3 is decreased
in 30% to 50% of patients with heterozygous CFH
mutations.
CFH is in close proximity to the genes CFHR1 to
CFHR5, which encode 5 CFH-related proteins. CFH
and the CFHR genes share a high degree of sequence
identity. This homology predisposes to gene conver-
sion and genomic rearrangements due to nonallelic
homologous recombination and microhomology-
mediated end joining. The most common rearrange-
ment results in a hybrid gene comprising the ﬁrst 21
CFH exons and the last 2 CFHR1 exons. Another
hybrid gene consisting of the ﬁrst 22 CFH exons and
the last 5 CFHR3 exons has been reported in aHUS.
More recently, a novel nonallelic homologous
recombination event that forms a reverse hybrid gene364consisting of the ﬁrst 5 exons of CFHR1 and the last
exon of CFH has been reported in 2 patients with
familial aHUS. Overall, hybrid genes account for 3%
to 5% of patients with aHUS (Table 2) and result in
gene products with decreased complement-regulatory
activity on endothelial surfaces.
An acquired CFH defect due to anti-CFH immu-
noglobulin G (IgG) autoantibodies accounts for 5% to
10% and 25% to 50% of adult and pediatric aHUS
cases, respectively (Table 2). Ninety percent of pa-
tients with anti-CFH antibodies have a complete
deﬁciency of CFHR1 and CFHR3 associated with a
homozygous deletion of CFHR1 and CFHR3, a
polymorphism also observed in 4% of healthy in-
dividuals of European ancestry who do not develop
anti-CFH antibodies. In more recent studies, some
patients with aHUS with CFHR1 deﬁciency resulting
from CFHR1 mutations or from a deletion including
CFHR1 and CFHR4 have been reported to develop
anti-CFH antibodies. This may suggest that CFHR1
deﬁciency is the predominant predisposing factor for
autoantibodies (Table 2).
Epitope mapping initially suggested that the anti-
CFH antibodies bound predominantly to SCR19-20;
however, it recently has been reported that the anti-
body response is polyclonal, involving multiple epi-
topes throughout CFH. Cross-reactivity with CFHR1
and CFHR2 has also been reported. Functional con-
sequences of anti-CFH antibodies include reduced
CFH binding to C3b and other C3 fragments and
perturbed CFH-mediated cell-surface protection. C3
levels are decreased in 40% to 60% of patients with
anti-CFH antibodies.Am J Kidney Dis. 2015;66(2):359-375
Complement-Dependent Glomerular DiseaseMembrane Cofactor Protein Mutations
Membrane cofactor protein (MCP) is a surface
complement regulator that exerts cofactor activity for
the cleavage of C3b and C4b by CFI (Fig 2A). The
association between mutations in the MCP gene
(CD46) and aHUS were ﬁrst described by Noris et al
and Richards et al in 2003. MCP gene mutations
account for 8% to 10% of cases, and most are het-
erozygous (http://www.FH-HUS.org; Table 2). The
majority cluster in SCR1 to 4, which are extracellular
domains critical for regulation. Most patients
(w75%) have decreased MCP expression on periph-
eral leukocytes. Less frequently, MCP expression is
normal, but the mutant proteins bind C3b weakly and
have low cofactor activity. C3 levels in patients with
mutant forms of MCP are most often normal, an ex-
pected ﬁnding because MCP alterations result in local
surface complement activation, with no substantial
effect in the ﬂuid phase (Fig 2B).
CFI Mutations
CFI is a serum serine protease that cleaves C3b and
C4b in the presence of its cofactors. CFI mutations
were ﬁrst described in 2004 and account for 4% to 8%
of patients with aHUS (Table 2). Eighty percent of
mutations cluster in the serine protease domain.
Approximately 50% block protein secretion; some
mutants are secreted but have dysfunctional proteo-
lytic activity with altered degradation of C3b/C4b in
the ﬂuid phase and on cell surfaces (Fig 2B). C3
levels can be decreased (in 20%-30% of patients).
Mutations in the Alternative Pathway C3 Convertase
Components
Heterozygous gain-of-function mutations affecting
genes encoding the alternative pathway C3 convertase
components CFB and C3 were ﬁrst described in 2007
and 2008, respectively. C3 mutations have been
found in 4% to 8% of patients with aHUS (Table 2).
Most C3 mutations induce a defect in the ability of
complement regulators (in particular MCP) to bind to
C3b, preventing its cleavage to iC3b (Table 2; Fig
2B). More recent studies described 2 C3 mutants
that bind CFB with higher afﬁnity, resulting in a more
stable C3 convertase complex. C3 mutations result in
increased complement activation on glomerular
endothelium and platelets. Serum C3 levels are low in
w70% of patients.
Mutations in CFB are rare (1%-4% of patients with
aHUS; Table 2). These mutations result in a “super-B,”
which forms a hyperactive C3 convertase that is
resistant to decay by complement regulators (Table 2;
Fig 2B), with enhanced complement activation at
endothelial cell surfaces. However, a more recent
functional study revealed that 9 of 15 CFB genetic
changes identiﬁed in patients with aHUS lead to aAm J Kidney Dis. 2015;66(2):359-375normal C3 convertase in vitro. Patients with CFB
mutations experience ongoing activation of the alter-
native pathway and usually have very low C3 levels.
Thrombomodulin Mutations
Thrombomodulin (THBD) is an endothelial glyco-
protein that favors the thrombin-mediated activation
of both protein C and TAFI, the thrombin-activatable
ﬁbrinolysis inhibitor responsible for inactivating C3a
and C5a. THBD has also been shown to downregulate
the alternative pathway by amplifying CFH cofactor
activity (Fig 2A).
Heterozygous mutations in THBD were ﬁrst re-
ported in 2009 and have been found in 3% to 4% of
patients with aHUS (Table 2). Cells expressing these
mutants inactivate C3b and activate TAFI less efﬁ-
ciently than cells expressing wild-type THBD. These
data document a functional link between complement
and coagulation. C3 levels are decreased in half the
patients with THBD mutations.
Combined Complement Abnormalities and Susceptibility
Factors
Mutations in more than 1 complement gene have
been reported in a few patients. In a report from 4
European cohorts, 27 of 795 (3.4%) patients with
aHUS had combined mutations. Of note, only 8% to
10% of patients with CFH, C3, or CFB mutations also
had a mutation in other genes. These data indicate that
CFH, C3, or CFB mutations alone may be enough to
cause aHUS. By contrast, about a quarter of patients
with a CD46 (MCP) or CFI mutation had a second or
third mutation in other complement genes. Thus,
screening of all known disease-associated genes is
recommended in patients with aHUS.
A number of single-nucleotide polymorphisms
(SNPs; polymorphisms are deﬁned as genetic changes
with .1% frequency in ethnically matched control
groups) have been associated with aHUS. The CFH
haplotype H3 (Table 3) increases the risk of aHUS 2-
to 4-fold. Functional studies have documented that
one of the polymorphisms within this haplotype, a
variant in which there is a valine at amino acid 62,
leads to slightly decreased cofactor activity compared
with proteins in which isoleucine is at this position.
The MCP2 haplotype of MCP (Table 3) has been
associated with a 2- to 3-fold increased risk of aHUS.
In reporter gene studies, this haplotype reduced
transcriptional activity by 25%. A CFHR1 poly-
morphism (CFHR1*B) is strongly associated with
aHUS in the homozygous state (Table 3). Because
CFHR1*B renders SCR3 of CFHR1 identical to
SCR18 of CFH, it has been suggested that CFHR1*B
variant may compete with CFH at the glomerular
endothelium, thus impairing complement regulation.365
Table 3. Risk and Protective SNPs and Haplotypes for aHUS and DDD
Gene Variant (SNP) Haplotype Effect Disease
CFH 2332T (c.2332C.T) Risk aHUS
184G (c.184G.A, p.V62I) Risk DDD
1204C (c.1204T.C, p.Y402H) Risk DDD
2016G (c.2016A.G, p.Q672Q) Risk aHUS
2808T (c.2808G.T, p.E936D) Risk aHUS
H1 (CGCAG) Risk DDD
H2 (CATAG) Protective aHUS and DDD
H3 (TGTGT) Risk aHUS
CFHR1 469T (c.469C.T, p.H157Y)
475G (c.475C.G, p.L159V)
523C (c.532G.C, p.E175Q)
CFHR1*B (TGC) Risk aHUS
MCP 2652G (c.2652A.G) Protective C3GN and IC-MPGN
*897C (c.*897T.C) Risk aHUS
MCP1 (AT) Risk C3GN and IC-MPGN
MCP2 (GC) Risk aHUS
MCP3 (GT) Protective C3GN and DDD
C3 304G (c.304C.G, p.R102G) Risk DDD
941T (c.941C.T, p.P314L) Risk DDD
Note: Descriptions of SNPs first include a shorthand for referring to the variant, and in parentheses, its full description at the coding
DNA (c) level and, if applicable, at the protein (p) level; example: 184G (c.184G.A, p.V62I) means a guanine to adenine substitution at
the 184th nucleotide of the coding sequence, leading to a substitution of an isoleucine for a valine at amino acid 62. A minus sign
indicates a position upstream of the translation start site, while an asterisk indicates a position downstream of the translation stop
codon (ie, these upstream and downstream variants would both be in noncoding regions of the gene). The letters in parentheses after
each haplotype (ie, a set of variants inherited together) give the identity of the nucleotide at each SNP listed for the gene in this table.
For example, haplotype H3 (TGTGT) comprises a thymine at c.2332C.T, a guanine at c.184G.A, a thymine at c.1204T.C, a
guanine at c.2016A.G, and a thymine at c.2808G.T. Data are from Abrera-Abeleda et al (J Am Soc Nephrol. 2011;22:1551-1559),
Pickering et al (J Exp Med. 2007;204:1249-1256), and Servais et al (Kidney Int. 2012;82:454-464).
Abbreviations: aHUS, atypical hemolytic uremic syndrome; C3GN, C3 glomerulonephritis; CFH, complement factor H; CFHR,
complement factor H–related; DDD, dense deposit disease; IC-MPGN, immune-complex–mediated membranoproliferative glomer-
ulonephritis; MCP, membrane cofactor protein; SNP, single-nucleotide polymorphism.
Noris and RemuzziDiacylglycerol Kinase ε Mutations
In 2013, homozygous or compound heterozygous
mutations in the gene encoding diacylglycerol kinase
ε (DGKE) were reported to cosegregate with aHUS in
9 unrelated kindreds (Table 2). Mutation carriers who
presented with aHUS before 1 year of age had
persistent hypertension, hematuria, and proteinuria
and developed chronic kidney disease with age.
DGKE is expressed in endothelium, platelets, and
podocytes. It is apparently unrelated to the comple-
ment cascade, and a very recent study has documented
that DGKE silencing in human cultured endothelial
cells induces a proinﬂammatory and prothrombotic
phenotype, increases endothelial apoptosis, and im-
pairs migration and angiogenesis. DGKE knockdown
is reported to decrease the expression of the comple-
ment regulator MCP on endothelial cells, but does not
induce complement deposition.
Nevertheless, there is some evidence for a connec-
tion between DGKE and complement systems. In a
family with 2 affected children, one child had a lower-
than-normal C3 level at onset. In addition, DGKE
mutations combined with mutations in THBD or C3
have been reported in children with severe aHUS
who responded to anticomplement therapy. These
observations suggest that in patients with DGKE366mutations, complement gene mutations play a role in
determining aHUS severity and therapeutic response.
Additional Readings
» Bresin E, Rurali E, Caprioli J, et al. Combined complement
gene mutations in atypical hemolytic uremic syndrome inﬂu-
ence clinical phenotype. J Am Soc Nephrol. 2013;24(3):475-
486.
» Bruneau S, Neel M, Roumenina LT, et al. Loss of DGKε
induces endothelial cell activation and death independently of
complement activation. Blood. 2015;125(6):1038-1046.
» Caprioli J, Castelletti F, Bucchioni S, et al. Complement
factor H mutations and gene polymorphisms in haemolytic
uraemic syndrome: the C-257T, the A2089G and the G2881T
polymorphisms are strongly associated with the disease. Hum
Mol Genet. 2003;12(24):3385-3395.
» Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin
mutations in atypical hemolytic-uremic syndrome. N Engl J
Med. 2009;361(4):345-357.
» Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H
autoantibodies associated with atypical hemolytic uremic
syndrome. J Am Soc Nephrol. 2005;16(2):555-563.
» Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al.
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» Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Muta-
tions in complement C3 predispose to development of atypical
hemolytic uremic syndrome. Blood. 2008;112(13):4948-4952.
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Gain-of-function mutations in complement factor B areAm J Kidney Dis. 2015;66(2):359-375
Complement-Dependent Glomerular Diseaseassociated with atypical hemolytic uremic syndrome. Proc
Natl Acad Sci U S A. 2007;104(1):240-245.
» Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al. Recessive
mutations in DGKE cause atypical hemolytic-uremic syn-
drome. Nat Genet. 2013;45(5):531-536.
» Marinozzi MC, Vergoz L, Rybkine T, et al. Complement
factor B mutations in atypical hemolytic uremic syndrome,
disease-relevant or benign? Blood. 2014;25(9):2053-5065.
» Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic
uraemic syndrome and an MCP mutation. Lancet.
2003;362(9395):1542-1547.
» Richards A, Kemp EJ, Liszewski MK, et al. Mutations in hu-
man complement regulator, membrane cofactor protein
(CD46), predispose to development of familial hemolytic
uremic syndrome. Proc Natl Acad Sci U S A. 2003;100:12966-
12971.
» Schramm EC, Roumenina LT, Rybkine T, et al. Mapping
interactions between complement C3 and regulators using
mutations in atypical hemolytic uremic syndrome. Blood.
2015;125:2359-2369.
» Valoti E, Alberti M, Tortajada A, et al. A novel atypical
hemolytic uremic syndrome-associated hybrid CFHR1/CFH
gene encoding a fusion protein that antagonizes factor H-
dependent complement regulation. J Am Soc Nephrol.
2015;26(1):209-219.
» Venables JP, Strain L, Routledge D, et al. Atypical haemo-
lytic uraemic syndrome associated with a hybrid complement
gene. PLoS Med. 2006;3(10):e431.
» Warwicker P, Goodship TH, Donne RL, et al. Genetic studies
into inherited and sporadic hemolytic uremic syndrome.
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Restricted Cell-Surface Complement Activation in
aHUS Causes Microvascular Thrombosis
aHUS-associated mutant forms of CFH, MCP, CFI,
and THBD cannot fully regulate the alternative
pathway on host cells, resulting in C3 and C5b-9
deposition on cell surfaces (Fig 2B). By contrast,
aHUS-associated mutant proteins effectively regulate
complement in the ﬂuid phase, which would explain
the normal or near-normal circulating C3 levels in
many mutation carriers. Gain-of-function mutations
of CFB and C3 form a C3 convertase resistant to
decay by endothelial cell regulators. In an ex vivo
test, we documented that serum from patients with
aHUS induced intense C5b-9 deposition on cultured
endothelial cells; this occurred in 100% of patient
samples tested, independent of the type of mutation
and the gene involved. Such data conﬁrm that local
complement activation on endothelial cells rather than
in ﬂuid phase plays a pathogenetic role in aHUS. Of
note, sera from patients without identiﬁed mutations
also induce C5b-9 endothelial deposits, indicating that
there are still unrecognized genetic or acquired com-
plement abnormalities leading to aHUS.
Besides its well-known lytic effect, C5b-9 can
mediate endothelial cell injury and dysfunction by
many mechanisms. Sublytic C5b-9 induces secre-
tion of multimers of von Willebrand factor, stimu-
lates prothrombinase and tissue factor activity, and
upregulates adhesion molecules, which generate aAm J Kidney Dis. 2015;66(2):359-375prothrombotic endothelial cell surface that activates
platelets and ﬁbrin deposition (Fig 2B). Furthermore,
C5b-9 induces cell retraction, exposing the underlying
prothrombotic matrix, and can directly activate plate-
lets. The pathogenetic role of C5b-9 and the other C5
activation products in aHUS was eventually conﬁrmed
by clinical trials showing that the monoclonal antibody
eculizumab, through blockade of C5 cleavage, protects
against microvascular thrombosis and radically im-
proves the outcome of patients with aHUS.
Additional Readings
» Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement
proteins C5b-9 induce secretion of high molecular weight
multimers of endothelial von Willebrand factor and trans-
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surface. J Biol Chem. 1989;264(15):9053-9060.
» Kerr H, Richards A. Complement-mediated injury and pro-
tection of endothelium: lessons from atypical haemolytic
uraemic syndrome. Immunobiology. 2012;217(2):195-203.
» Legendre CM, Licht C, Muus P, et al. Terminal complement
inhibitor eculizumab in atypical hemolytic-uremic syndrome.
N Engl J Med. 2013;368(23):2169-2181.
» Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H
reduce binding afﬁnity to C3b and heparin and surface
attachment to endothelial cells in hemolytic uremic syn-
drome. J Clin Invest. 2003;111(8):1181-1190.
» Noris M, Galbusera M, Gastoldi S, et al. Dynamics of
complement activation in aHUS and how to monitor eculi-
zumab therapy. Blood. 2014;124(11):1715-1726.
» Roumenina LT, Jablonski M, Hue C, et al. Hyperfunctional
C3 convertase leads to complement deposition on endothelial
cells and contributes to atypical hemolytic uremic syndrome.
Blood. 2009;114(13):2837-2845.
» Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL.
Complement-mediated regulation of tissue factor activity in
endothelium. J Exp Med. 1995;182(6):1807-1814.
» Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunc-
tion in patients with atypical hemolytic uremic syndrome
contributes to complement deposition on platelets and their
activation. Blood. 2008;111(11):5307-5315.
Incomplete Penetrance and Triggering Factors
Penetrance of aHUS has been found to be w50%
for individuals who carry complement gene muta-
tions. Thus, it can be inferred that although the ge-
netic alterations are important, they are not sufﬁcient
to cause aHUS. As discussed previously, patients may
carry mutations in multiple genes or have both genetic
abnormalities and autoantibodies; in addition, they
may carry a mutation in combination with common
at-risk genetic variants in CFH or MCP. In family
studies, it has been observed that the penetrance of
aHUS increases as the number of alterations increases
in a given individual. Even in individuals with mul-
tiple genetic/acquired risk factors, aHUS may not
occur until adulthood, indicating that a triggering
event that activates the alternative pathway is required
for disease manifestation in genetically susceptible
individuals (the multiple hits theory).367
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» Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al.
Predisposition to atypical hemolytic uremic syndrome in-
volves the concurrence of different susceptibility alleles in the
regulators of complement activation gene cluster in 1q32.
Hum Mol Genet. 2005;14(5):703-712.
» Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-
associated hemolytic uremic syndrome revisited in the
era of complement gene mutations. J Am Soc Nephrol.
2010;21(5):859-867.
» Noris M, Galbusera M, Gastoldi S, et al. Dynamics of
complement activation in aHUS and how to monitor eculi-
zumab therapy. Blood. 2014;124(11):1715-1726.
HUS ASSOCIATED WITH COBALAMIN DEFICIENCY
A rare autosomal recessive form of HUS results
from mutations in the MMACHC gene, which is
involved in cobalamin C metabolism (Table 1). The
biochemical characteristics are hyperhomocysteinemia
and methylmalonic aciduria. Patients generally present
within days or months of birth with symptoms of
failure to thrive, poor feeding, and vomiting. This is
followed by rapid deterioration, caused by metabolic
acidosis, gastrointestinal bleeding, hemolytic anemia,
thrombocytopenia, severe respiratory and liver failure,
and decreased kidney function. It has been suggested
that the marked elevation in homocysteine level may
contribute to the pathogenesis of the vascular lesions.
Additional Reading
» Geraghty MT, Perlman EJ, Martin LS, et al. Cobalamin C
defect associated with hemolytic uremic syndrome. J Pediatr.
1992;120(4):934-937.
SECONDARY FORMS OF HUS
A variety of conditions have been reported in
association with HUS, including viral (HIV [human
immunodeﬁciency virus] and H1N1 inﬂuenza A),
parasitic, and other bacterial infections; oral contra-
ceptives; calcineurin inhibitors; illicit drugs; cancer
chemotherapy and ionizing radiation; malignant
hypertension; bone marrow or solid-organ trans-
plantation; autoimmune disorders; malignancy; pre-
gnancy; and HELLP (hemolysis, elevated liver
enzymes, and low platelets) syndrome. These forms
are called secondary HUS (Table 1), although this
classiﬁcation does not account for the evidence that
some of these conditions often act as a trigger of
aHUS in individuals who have a genetic background
predisposing to complement activation. For instance,
a substantial proportion of HUS cases occurring
during pregnancy, postpartum, or de novo in the
kidney transplant have been found to be associated
with complement gene mutations. Along with this,
triggering or underlying clinical conditions have
been reported in up to 70% of patients with com-
plement gene mutations, providing evidence that368disease development requires both a genetic predis-
position and a triggering event.
Additional Reading
» Besbas N, Karpman D, Landau D, et al. A classiﬁcation
of hemolytic uremic syndrome and thrombotic thrombo-
cytopenic purpura and related disorders. Kidney Int.
2006;70(2):423-431.
MEMBRANOPROLIFERATIVE
GLOMERULONEPHRITIS
MPGN is an uncommon cause of chronic protei-
nuric nephropathy (the incidence is w5 per million
persons per year) that may be primary or secondary to
hepatitis C virus and other infections, autoimmune
diseases, and malignancies. The onset of MPGN can
occur from childhood to late adulthood. The clinical
presentation is variable and ranges from asymptom-
atic hematuria and proteinuria to acute nephritic
syndrome, nephrotic syndrome, chronic kidney dis-
ease, or even rapidly progressing glomerulonephritis
resulting in end-stage renal disease.
The high variability of clinical presentation and
course is likely caused by differences in the patho-
genesis of the disease, the histologic lesion in the
kidney, and the timing of the diagnosis (that is based
on kidney biopsy) relative to the clinical course.
Additional Readings
» Doutrelepont JM, Adler M, Willems M, et al. Hepatitis C
infection and membranoproliferative glomerulonephritis.
Lancet. 1993;341(8840):317.
» Sethi S, Fervenza FC. Membranoproliferative glomerulone-
phritis: pathogenetic heterogeneity and proposal for a new
classiﬁcation. Semin Nephrol. 2011;31(4):341-348.
Histologic Features and Classiﬁcation
MPGN is characterized by mesangial hyper-
cellularity and matrix expansion, with thickening of
glomerular capillaries (with the formation of double
contours), interposition of leukocytes and mesangial
cells, and synthesis of new GBM resulting in lobular
accentuation of glomerular tufts. This pattern of
injury results from deposition of immune complexes
and/or complement factors in the glomerular mesan-
gium and along the glomerular capillary walls and is
easily recognized by light and immunoﬂuorescence
microscopy.
Traditionally, on the basis of electron microscopy
ﬁndings, MPGN was classiﬁed as type I, with sub-
endothelial electron-dense deposits; type II (also called
dense deposit disease [DDD]), with intramembranous
highly electron-dense deposits; and type III, with both
subendothelial and subepithelial deposits. These cate-
gories had limited prognostic value because of their
complexity and the occurrence of features suggestive of
more than 1 type in the same biopsy samples.Am J Kidney Dis. 2015;66(2):359-375
Complement-Dependent Glomerular DiseaseA new classiﬁcation based on the pathogenesis and
composition of glomerular deposits as analyzed by
immunoﬂuorescence microscopy has been proposed.
MPGN associated with substantial immunoglobulin
deposits has been termed immune-complex–mediated
MPGN and is commonly associated with chronic in-
fections or autoimmune diseases (Fig 5). In these
secondary forms, careful characterization of deposits
can often help identify the underlying cause. Deposits
of IgM, IgG, C3, and k and l light chains are typi-
cally found in MPGN associated with hepatitis C
virus infection. Multiple immunoglobulins and com-
plement proteins (IgG, IgM, IgA, C1q, C3, and k and
l light chains) are also observed in MPGN associated
with autoimmune diseases. However, monotypic
immunoglobulin with k and l light chain restriction is
observed in MPGN associated with monoclonal
gammopathy. Immune-complex–mediated MPGN
has been considered to include most cases of MPGN
types I and III according to the older classiﬁcation,
with electron microscopy typically revealing mesan-
gial and subendothelial deposits and, in some cases,
intramembranous and subepithelial deposits.
MPGN cases that present clear glomerular C3
staining with absent or scanty immunoglobulins are
considered complement-mediated MPGN and are
referred to as C3Gs (Fig 5). C3G is less common than
immune-complex–mediated MPGN, has a prevalence
of about 1-2 cases per million inhabitants, and is
further divided on the basis of the quality of the de-
posits seen in glomeruli on electron microscopy
(Fig 5). DDD is diagnosed in cases with distinctive
highly electron-dense osmiophilic deposits that are
typically found within the GBM. These deposits
extend along the central part of the GBM, but may
also involve the subendothelial and subepithelial re-
gion. Globular deposits appear in the mesangium and
in about half the patients with DDD, are also seen inMPGN IC-mediated
Autoimmune diseases
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Monoclonal gammopathies
Dysproteinemia
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C3
Figure 5. Schematic representation of membranoproliferative glo
rescence findings. *Prevalent. Abbreviations: DDD, dense deposit d
Am J Kidney Dis. 2015;66(2):359-375Bowman capsule and the tubular basement membrane
(Fig 6A).
Cases of C3G that lack the electron-dense deposits
of DDD are called C3 glomerulonephritis. In C3
glomerulonephritis, deposits have subendothelial and
sometimes subepithelial and intramembranous local-
ization (Fig 6B), morphologic characteristics likely
resembling MPGN types I and III. Thus, with the
exception of DDD, electron microscopy cannot dis-
tinguish between immune-complex–mediated MPGN
and C3G.
However, immunoﬂuorescence microscopy cannot
always conﬁrm a diagnosis because immunoglobulins
may be present in glomeruli of patients with C3G.
Small amounts of immunoglobulin may become trap-
ped in areas of sclerosis or in podocytes of patients
with proteinuric glomerular diseases, and about one-
third of patients with DDD have glomerular IgG
staining. Thus, a subsequent broader classiﬁcation of
C3G proposed by a recent consensus report suggested
including all cases that have dominant immunoﬂuo-
rescence microscopy staining of C3 of 2 or more orders
of magnitude greater than any other immune reactants
(using a scale of 0-3). Even with this broader classiﬁ-
cation, a substantial proportion (20%) of patients with
DDD would not be classiﬁed as having C3G.
Conversely, isolated staining for C3 on immunoﬂuo-
rescence microscopy may be observed in cases of
postinfectious glomerulonephritis. Therefore, the issue
ofMPGN classiﬁcation has not yet been fully resolved.
Additional Readings
» Anders D, Thoenes W. Basement membrane-changes in
membranoproliferative glomerulonephritis: a light and elec-
tron microscopic study. Virchows Arch A Pathol Anat Histol.
1975;369(2):87-109.
» Barbour TD, Pickering MC, Terence Cook H. Dense
deposit disease and C3 glomerulopathy. Semin Nephrol.
2013;33(6):493-507.C3
C3 glomerulopathies
DDD
C3 glomerulonephritis
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±
merulonephritis (MPGN) reclassification based on immunofluo-
isease; IC-mediated, immune complex–mediated.
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Figure 6. Electron microscopy images of glomeruli from patients with dense deposit disease (DDD) or C3 glomerulonephritis. (A)
DDD. Osmiophilic wavy dense deposits occurring in the glomerular basement membrane and also the mesangium (white arrows). (B)
C3 glomerulonephritis. Intramembranous and subendothelial deposits (white arrows).
Noris and Remuzzi» Cook HT, Pickering MC. Histopathology of MPGN and C3
glomerulopathies. Nat Rev Nephrol. 2015;11(1):14-22.
» Hou J, Markowitz GS, Bomback AS, et al. Toward a working
deﬁnition of C3 glomerulopathy by immunoﬂuorescence.
Kidney Int. 2014;85(2):450-456.
» Pickering MC, D’Agati VD, Nester CM, et al. C3 glomer-
ulopathy: consensus report. Kidney Int. 2013;84(6):1079-
1089.
» Sethi S, Fervenza FC. Membranoproliferative glomerulone-
phritis—a new look at an old entity. N Engl J Med.
2012;366(12):1119-1131.
Pathophysiology of Immune-Complex–Mediated
MPGN
Infectious Causes of Complement Activation
Most cases of immune-complex–mediated MPGN
in the adult population are attributable to chronic viral
infections such as those due to hepatitis B or C virus.
Chronic bacterial infections, like those caused by
staphylococcus, Mycobacterium tuberculosis, and
streptococci, and protozoal diseases, such as malaria
and schistosomiasis, are also associated with MPGN,
particularly in developing countries.
These conditions are characterized by persistent
antigenemia and the formation of antigen-antibody
immune complexes. It is generally accepted that im-
mune complexes initiate the classical pathway of
complement by activating C1, which triggers forma-
tion of the C3 convertase of the classical pathway,
resulting in deposition of immune complexes and C3
activation fragments in the glomerulus, and ﬁnally to
the generation of the terminal C5b-9 complex. This
phase is followed by an inﬂux of leukocytes, favored
by formation of the C3a and C5a anaphylatoxins, that
damages capillary walls by the release of cytokines
and proteases, leading to proteinuria and hematuria.
As a reparative reaction, new basement membrane is
then formed, which is associated with entrapment of370immune complexes, complement products, and cell
debris.
Autoimmune Causes of Complement Activation
MPGN can also be triggered by circulating im-
mune complexes associated with autoimmune dis-
eases such as systemic lupus erythematosus, mixed
cryoglobulinemia, Sjögren syndrome, mixed cry-
oglobulinemia, and scleroderma. Immune complexes
activate the classical complement pathway and
initiate the same cascade of events observed in
MPGN forms secondary to chronic infections.
Complement Activation by Monoclonal Immunoglobulins
MPGN can be associated with deposition of
monoclonal immunoglobulins, which may occur in
the setting of monoclonal gammopathy of undeter-
mined signiﬁcance, chronic lymphocytic leukemia,
low-grade B-cell lymphoma, and multiple myeloma.
Monoclonal gammopathies are associated with com-
plement activation. The mechanism underlying this
effect is poorly understood, but likely involves acti-
vation of the alternative pathway by the aberrant
immunoglobulin. Of note, monoclonal l light chains
from a patient with DDD have been reported to
activate the alternative pathway directly through an
interaction with CFH.
Additional Readings
» Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic
lambda light chain dimer: a unique human miniautoantibody
against complement factor H. J Immunol. 1999;163(8):4590-
4596.
» Sethi S, Nester CM, Smith R. Membranoproliferative
glomerulonephritis and C3 glomerulopathy: resolving the
confusion. Kidney Int. 2012;81(2):434-441.
» Sethi S, Zand L, Leung N, et al. Membranoproliferative
glomerulonephritis secondary to monoclonal gammopathy.
Clin J Am Soc Nephrol. 2010;5(3):770-782.Am J Kidney Dis. 2015;66(2):359-375
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Figure 7. Model for mechanisms leading from fluid-phase impaired regulation of the alternative pathway to C3 glomerulopathies.
Mutations in the factor H (FH) gene causing very low FH levels or impaired FH cofactor activity, or C3 nephritic factor (C3NeF) and C3
gain-of-function mutations that render the alternative pathway C3 convertase resistant to FH-mediated dissociation; all result in uncon-
trolled fluid-phase alternative pathway activation and finally in the formation of the fluid-phase terminal complement pathway complex
(with vitronectin or clusterin bound; sC5b-9). The injury likely develops upon deposition in the subendothelial space of C3 activating
products and the terminal complement complex after transfer through the fenestrated endothelium (dashed line). Abbreviations:
FB, factor B; FI, factor I; MCP, membrane cofactor protein.
Complement-Dependent Glomerular DiseasePathophysiology of C3G
Hyperactivation of the alternative pathway of
complement has been proposed as a primary cause of
C3G and may be associated with autoantibodies like
the C3 nephritic factors (C3Nefs) or with defects in
genes encoding complement proteins and regulators.
However, the distinction between immune-
complex–mediated MPGN and C3G as diseases of
classical and alternative pathway activation has been
recently questioned by the observation that alternative
pathway abnormalities with low C3, C3Nef, and/or
mutations in complement genes are present as
frequently in patients with immune-complex–
mediated MPGN as in those with C3G. These ﬁnd-
ings indicate that the 2 diseases may show more
commonality than previously recognized, with dys-
regulation of the alternative pathway playing a pri-
mary pathogenetic role. This possibility is further
supported by reports of immune-complex–mediated
MPGN associated with complete CFH deﬁciency. It
has been hypothesized that in predisposed individuals
with genetic or acquired complement alternative
pathway dysregulation, immune complex depositionAm J Kidney Dis. 2015;66(2):359-375initially triggers the classical pathway and then
chronic complement activation and kidney injury is
sustained through the alternative pathway.
Autoimmune Alternative Pathway Abnormalities
Upregulated activity of the complement alternative
pathway can be caused by autoantibodies targeted at
either C3 convertase or its components or at regula-
tory proteins. The ﬁrst described autoantibody was
C3Nef, which binds to a neoepitope on the C3 con-
vertase of the alternative pathway component C3bBb,
stabilizing it against CFH-mediated decay and pro-
longing its C3 cleaving action (Fig 7). A second type
of C3Nef was found to display slower C3 activation
and dependence on properdin for convertase stabili-
zation. Properdin-independent C3Nefs have been
found to have no effect on C5 cleavage and terminal
pathway activity, whereas properdin-dependent
C3Nef enhances C5 convertase activity. C3Nefs are
found in .80% of patients with DDD and 40%
to 50% of patients with C3 glomerulonephritis or
immune-complex–mediated MPGN. However, in
most studies, the presence of C3Nefs has not been371
Noris and Remuzzifound to correlate with disease outcome. In a family
with MPGN and partial lipodystrophy, C3Nef was
detected in all members with lipodystrophy but did
not segregate with the renal phenotype. In addition,
C3NeFs have been also found in patients with
meningococcal meningitis, lupus nephritis, and even
healthy individuals and asymptomatic family mem-
bers of patients with DDD, indicating that the pres-
ence of C3NeFs alone is not sufﬁcient for the
development of C3G. Whether C3Nefs are the pri-
mary causes of the disease or are secondarily formed
as consequences of the disease process is still un-
clear. Additional studies are needed to deﬁne the
signiﬁcance of C3NeFs in the pathophysiology of
immune-complex–mediated MPGN and C3G and
their relationship to disease course and treatment.
Autoantibodies that bind to native CFB and stabi-
lize the alternative pathway C3 convertase, or target
both CFB and C3b, have been described in patients
with DDD. Anti-CFH autoantibodies have been
identiﬁed in a few patients with immune-complex–
mediated MPGN, DDD, and C3 glomerulonephritis.
Of note, the autoantibodies bind predominantly to the
amino-terminal complement regulatory domain of
CFH, in contrast to aHUS-associated autoantibodies,
which mostly bind the CFH carboxy-terminal surface
recognition domain. Altogether, both C3Nef and au-
toantibodies against either C3 convertase components
or CFH stabilize the convertase and prolong its half-
life, preventing its dissociation and degradation and
thereby resulting in uncontrolled alternative pathway
activation in the ﬂuid phase (Fig 7).
Genetic Alternative Pathway Abnormalities
The reports of familial cases of C3G and immune-
complex–mediated MPGN (MPGN types I and III)
indicate a genetic basis of the diseases, although the
genetic defect has been characterized in only a mi-
nority of patients.
Homozygous nonsense and missense CFH muta-
tions, causing either premature truncation of the pro-
tein or impaired protein secretion, respectively, have
been reported in a few familial cases of autosomal
recessive DDD or C3 glomerulonephritis and are
associated with very low or undetectable CFH plasma
levels. Homozygous carriers present with kidney
disease during infancy and have very low serum C3,
CFB, and C5 levels, consistent with massive ﬂuid-
phase alternative pathway activation. In 2 young
daughters with C3 glomerulonephritis from consan-
guineous Turkish parents, a homozygous CFH mu-
tation caused a deletion of the lysine at amino acid
224 (in SCR4). These patients had very low C3 levels
but only slightly reduced CFH levels. Functional
studies revealed that the mutation produces a circu-
lating CFH protein with impaired binding to C3b and372defective decay accelerating and cofactor activities,
while its cell-binding activity is unaffected. Thus, this
mutation recapitulates the condition of dysregulated
alternative pathway ﬂuid-phase activation observed in
patients with complete CFH deﬁciency.
A C3 gain-of-function heterozygous mutation
leading to a 2–amino-acid deletion has been reported
in a mother and her 2 identical twin boys, all with
DDD. This C3 mutant is resistant to cleavage by C3
convertase and therefore cannot form activated C3b.
However, it forms the alternative pathway initia-
tion C3 convertase (C3[H2O]Bb; Fig 1) through the
normal “tick-over” process. This convertase is cap-
able of cleaving circulating wild-type C3 produced
from the normal allele, but is resistant to CFH-
mediated regulation, resulting in a dominant gain-of-
function effect of the mutation. Importantly, decay
of the mutant C3 convertase by the surface regulator
decay accelerating factor and MCP cofactor activity
for CFH-mediated C3b cleavage are not affected by
the C3 mutation, providing evidence that DDD in this
family results from alternative pathway dysregulation
restricted to the ﬂuid phase.
As a consequence of all the underlying abnormal-
ities reported, dysregulation of the alternative
pathway results in massive formation of complement
products in the circulation (Fig 7), such as C3b and
C5b-9, which are delivered indiscriminately to
endothelial surfaces, including glomeruli. The transfer
of these complement products and debris through the
fenestrated endothelium to subendothelial region and
the mesangium triggers glomerular inﬂammation
and leads to MPGN (Fig 7). This scenario appears
different from that associated with complement
gene mutations or anti-CFH autoantibodies in
aHUS, characterized by surface-restricted comple-
ment dysregulation.
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Sensitive and speciﬁc assays for C3 nephritic factors clarify
mechanisms underlying complement dysregulation. Kidney
Int. 2012;82(10):1084-1092.
» Zhang Y, Meyer NC, Wang K, et al. Causes of alternative
pathway dysregulation in dense deposit disease. Clin J Am
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aHUS, MPGN, and C3G: Different Diseases or a
Spectrum of Complement-Mediated Glomerular
Diseases?
The paradigm of the distinct pathogenetic mecha-
nisms of complement activation (cell surface vs ﬂuid
phase) leading to aHUS versus MPGN has been
recently thrown into question by a number of ﬁnd-
ings. A heterozygous nonhomologous allelic recom-
bination in the CFHR5 gene leading to internal
duplication of the initial 2 amino-terminal repeats of
CFHR5 (CFHR51212) has been detected in 2 families
with autosomal dominant C3G from the Troodos
Mountains of Cyprus; this disease was called CFHR5
nephropathy. A total of 91 carriers of the same
founder mutation from 16 apparently unrelated
Greek-Cypriot families was later reported, with dis-
ease penetrance of 90%. Of note, some carriers had a
previous diagnosis of MPGN type I. The same
abnormally large CFHR51212 protein was found in
association with C3 glomerulonephritis in a family
without Cypriot ancestry. However, the mutant pro-
tein derived from a genomic rearrangement distinct
from that seen in Cypriot CFHR5 nephropathy.
Another genomic duplication, in this case affecting
the CFHR1 gene, results in internal duplication of
the ﬁrst 4 amino-terminal domains of CFHR1
(CFHR11414) and segregates with C3G in a pedigree
with autosomal dominant transmission. CFHR1 to
CFHR5 circulate in plasma as homo- and hetero-
oligomeric complexes formed by interactions of
their conserved amino-terminal domains. CFHR1 to
CFHR5 homo- and hetero-oligomers can compete
with CFH for binding to C3b and other C3 activation
fragments. In mutant CFHR51212 and CFHR11414, the
dimerization motifs are duplicated, which results in
the formation of large multimeric complexes that
exhibit increased afﬁnity for surface-bound C3b and
exert enhanced competition with CFH.
However, why did these patients develop C3G
and not aHUS? It has been hypothesized that while
CFH mutations and CFH/CFHR genomic rearrange-
ments associated with aHUS impair binding of CFH
to most self-surfaces, C3G-associated mutant CFHRs
compete with CFH for binding to only a subset of
self-surfaces, but not to endothelial cell surfaces. Of
relevance, the mutant duplicated CFHR51212 interactsAm J Kidney Dis. 2015;66(2):359-375more with GBM-bound C3 than does wild-type
CFHR5. It has been suggested that there is contin-
uous activation of C3 along the GBM (spontaneous,
following a trigger, or both) that in normal conditions
is controlled by CFH. In the presence of abnormal
CFHR proteins, competition with CFH enables C3 to
accumulate along the GBM, causing accumulation of
C3 activation products and C3G.
In addition, hybrid genes (including CFHR3-1,
which encodes a fusion protein with the ﬁrst 2 SCRs
from CFHR3 and all 5 SCRs of CFHR1 [CFHR312-
CFHR1]), and a CFHR2/CFHR5 hybrid gene
(encoding the ﬁrst 2 SCRs of CFHR2 and all 9 SCRs
of CFHR5 [CFHR212-CFHR5]) have been reported in
affected individuals of a family with autosomal
dominant C3 glomerulonephritis (previously classi-
ﬁed as MPGN type III) and a family with autosomal
dominant DDD, respectively. The hybrid CFHR312-
CFHR1 and CFHR212-CFHR5 proteins can compete
with CFH for C3b binding and are able to deregulate
CFH function and activate the alternative pathway
C3 convertase both at the cell-surface level and in
plasma.
Furthermore, in a series of patients with immune-
complex–mediated MPGN and C3G, heterozygous
mutations in the CFH, CFI, and MCP genes have
been described in gene areas previously identiﬁed in
patients with aHUS, and conversely, mutations
affecting the CFH amino terminus and leading to
defective regulation both in the ﬂuid phase and at the
cell surface have been reported in patients with aHUS.
Finally, a homozygous mutation in CFH associated
with undetectable circulating CFH levels has been
documented in a patient who ﬁrst developed C3G and
later aHUS. Conversely, 2 children with CFH deﬁ-
ciency and aHUS have been reported to develop C3G
after kidney transplantation.
Altogether, these observations are suggestive of a
pathogenetic link between C3G, MPGN, and aHUS.
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factor H-related hybrid protein deregulates complement in
dense deposit disease. J Clin Invest. 2014;124(1):145-155.
» Gale DP, de Jorge EG, Cook HT, et al. Identiﬁcation of a
mutation in complement factor H-related protein 5 in pa-
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2010;376(9743):794-801.
» Goicoechea de Jorge E, Caesar JJ, Malik TH, et al. Dimer-
ization of complement factor H-related proteins modulates
complement activation in vivo. Proc Natl Acad Sci U S A.
2013;110(12):4685-4690.
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Incomplete Penetrance and Predisposing Factors
Complement gene mutations or rearrangements
have been identiﬁed in only w20% of patients with
immune-complex–mediated MPGN or C3G. In addi-
tion, the diseases do not develop in all mutation car-
riers in high-risk families, indicating that gene
mutations are predisposing factors and additional
genetic factors and environmental triggers are
required to induce the disease and determine the
phenotype.
Beside mutations, certain polymorphic variants
have also been linked to immune-complex–mediated
MPGN or C3G. Among these, the Y402H variant of
CFH (Table 3), which displays reduced binding and
complement regulation at cell surfaces, is over-
represented in patients with DDD, but no signiﬁcant
association has been detected with immune-complex–
mediated MPGN and C3 glomerulonephritis.
However, a signiﬁcant association has been found
between immune-complex–mediated MPGN and C3
glomerulonephritis and 1 SNP (c.-652A.G; Table 3)
located in the MCP promoter, with the G variant
under-represented in patients with immune-complex–
mediated MPGN and C3 glomerulonephritis. Finally,
2 C3 SNPs (R102G and P314L; Table 3) have been
associated with risk of DDD. Of relevance, in func-
tional studies, the R102G variant activates the alter-
native pathway more efﬁciently than the wild-type
protein. The likelihood of developing DDD increases
with the presence of 2 or more risk alleles in CFH and
C3. There have been previous reports not only of at-
risk haplotypes combining multiple SNPs in the CFH,
MCP, and C3 genes, but also of protective haplotypes
related to the CFH and MCP genes (Table 3).
Notably, all the mentioned gene variants and hap-
lotypes are different from those associated with
aHUS. It has been proposed that speciﬁc combina-
tions of risk and protective variants in alternative
pathway genes, called complotypes, contribute to set
levels of alternative pathway activity in plasma or at
the cell surface, thereby inﬂuencing disease risk and
phenotype. However, appropriately designed and
powered association studies are required to deﬁne
speciﬁc disease-associated complotypes.
Such studies will be relevant to reﬁne the classiﬁ-
cation of immune-complex–mediated MPGN and
C3G and also to predict response to therapies.
Additional Readings
» Abrera-Abeleda MA, Nishimura C, Frees K, et al. Allelic
variants of complement genes associated with dense deposit
disease. J Am Soc Nephrol. 2011;22(8):1551-1559.374» Heurich M, Martinez-Barricarte R, Francis NJ, et al. Com-
mon polymorphisms in C3, factor B, and factor H collaborate
to determine systemic complement activity and disease
risk. Proc Natl Acad Sci U S A. 2011;108(21):8761-8766.
Therapeutic Perspectives
Limitation of complement activation is a major
goal of current research into the treatment of C3G and
immune-complex–mediated MPGN; however, the
relative roles of upstream C3 activation products and
of the terminal complement complex are still not well
understood. At variance with the almost universal
response to eculizumab that is observed in aHUS,
case reports and a small trial have shown a clinical
response (reduction in serum creatinine and/or pro-
teinuria and histopathologic improvement) in some
but not all patients with C3G or immune-complex–
mediated MPGN either in native kidneys or recurring
in the kidney transplant. Elevated plasma sC5b-9
levels are reported as a potential marker of respon-
siveness. A trial comprising a greater number of well-
characterized patients is warranted to establish the
potential role of eculizumab in the treatment of C3G
and immune-complex–mediated MPGN.
Additional Readings
» Daina E, Noris M, Remuzzi G. Eculizumab in a patient with
dense-deposit disease. N Engl J Med. 2012;366(12):1161-
1163.
» Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology
after eculizumab in dense deposit disease and C3 GN. J Am
Soc Nephrol. 2012;23(7):1229-1237.
» Nester CM, Smith RJ. Treatment options for C3 glomerul-
opathy. Curr Opin Nephrol Hypertens. 2013;22(2):231-237.
» Radhakrishnan S, Lunn A, Kirschﬁnk M, et al. Eculizumab
and refractory membranoproliferative glomerulonephritis. N
Engl J Med. 2012;366(12):1165-1166.
» Vivarelli M, Emma F. Treatment of C3 glomerulopathy
with complement blockers. Semin Thromb Hemost.
2014;40(4):472-477.
» Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment
of dense-deposit disease. N Engl J Med. 2012;366(12):1163-
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CONCLUSIONS
The last decade has seen great advances in the
knowledge of the pathophysiologic role of comple-
ment activation in aHUS, immune-complex–mediated
MPGN, and C3G and has led to the discovery of an
effective therapy, at least in aHUS. However, there
are still a number of issues to be addressed.
In aHUS, we need to clarify whether and which
secondary forms are related to complement dysregu-
lation. Whether eculizumab should be a life-long
treatment or could be safely discontinued in a sub-
group of patients with aHUS is another crucial
issue in view of the impressively high cost of the
drug and the potential side effects. In this regard,
the recent identiﬁcation of a speciﬁc test of aHUSAm J Kidney Dis. 2015;66(2):359-375
Complement-Dependent Glomerular Diseaseserum-induced endothelial complement activation
could be of help to monitor disease activity and
personalize treatment.
In immune-complex–mediated MPGN and C3G,
biomarkers of alternative pathway activation more
speciﬁc than C3 deposits on immunoﬂuorescence
microscopy are needed to better discriminate immune
forms that are related to antigen–immune complex
reactions in glomeruli from complement-mediated
forms associated with alternative pathway activation.
The role of C3Nef as a cause or a consequence of the
disease process should be clariﬁed. Additional genetic
studies are required to clarify the role of complement
gene variants in determining disease predisposition. It
is likely that a subgroup of patients will beneﬁt from
C5 blockade, and biomarkers are required for early
identiﬁcation of potentially eculizumab-responsive
patients. However, emerging therapies that target
C3 convertase activity will be of major interest in
these diseases. Better understanding of the differentAm J Kidney Dis. 2015;66(2):359-375pathogenetic mechanisms underlying these conditions
will help optimize trial design with these agents.
Additional Reading
» Noris M, Galbusera M, Gastoldi S, et al. Dynamics of
complement activation in aHUS and how to monitor eculi-
zumab therapy. Blood. 2014;124(11):1715-1726.
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